Amalus Therapeutics
Description
Amalus Therapeutics aims to transform treatment for diseases linked to corrupted fibroblasts through its proprietary POKÉ target discovery platform, integrating forward genetics, mechanobiology, and data science. The company focuses on developing a novel, orally available small molecule designed to selectively target cancer-associated fibroblasts (CAFs), enhancing the effectiveness of existing cancer therapies. Currently in the seed phase and supported by recognized institutions, Amalus is pursuing funding to advance its lead asset towards regulatory submission by 2027.
Company members
Bart Roman; Paul Decraemer